Furthermore, high PAK1 expression was shown to be associated with poorer prognosis in AML patients without FLT3, IDH1, NPMc, or RAS mutation (P < 0.05, Figures 2C–F). The gene discussed is IDH1; the disease is acute myeloid leukemia.